NETEC Resource Library

Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020

Elemento

Click for External Resource*


Click to read full article*


*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.


Files for Download

rr7001a1-H.pdfrr7001a1-H.pdf

Item Type

Publicación

Terms of Use

By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.

Visor de documentos

Was this resource helpful?


Título

Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020

Descripción

This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the rVSVΔG-ZEBOV-GP Ebola vaccine (Ervebo) in the United States. The vaccine contains rice-derived recombinant human serum albumin and live attenuated recombinant vesicular stomatitis virus (VSV) in which the gene encoding the glycoprotein of VSV was replaced with the gene encoding the glycoprotein of Ebola virus species Zaire ebolavirus. Persons with a history of severe allergic reaction (e.g., anaphylaxis) to rice protein should not receive Ervebo. This is the first and only vaccine currently licensed by the Food and Drug Administration for the prevention of Ebola virus disease (EVD). These guidelines will be updated based on availability of new data or as new vaccines are licensed to protect against EVD.

ACIP recommends preexposure vaccination with Ervebo for adults aged ≥18 years in the U.S. population who are at highest risk for potential occupational exposure to Ebola virus species Zaire ebolavirus because they are responding to an outbreak of EVD, work as health care personnel at federally designated Ebola treatment centers in the United States, or work as laboratorians or other staff at biosafety level 4 facilities in the United States. Recommendations for use of Ervebo in additional populations at risk for exposure and other settings will be considered and discussed by ACIP in the future.

Autor

Fuente

Mary J. Choi; Caitlin M. Cossaboom; Amy N. Whitesell; Jonathan W. Dyal; Allison Joyce; Rebecca L. Morgan; Doug Campos-Outcalt; Marissa Person; Elizabeth Ervin; Yon C. Yu; Pierre E. Rollin; Brian H. Harcourt; Robert L. Atmar; Beth P. Bell; Rita Helfand; Inger K. Damon; Sharon E. Frey.

Fecha

2021-01-08

Citación

Choi MJ, Cossaboom CM, Whitesell AN, et al. Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2021;70(No. RR-1):1–12. DOI: http://dx.doi.org/10.15585/mmwr.rr7001a1external icon

Accesibilidad

Open Access at CDC.

Collection

Related Resource Topic Exhibits